Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04475523 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
A Phase 1 study, sponsored by Curis.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT04475523 is a Phase 1 study that has completed, run by Curis. The registered enrollment target is 26 participants.
The verdict
NCT04475523, a Phase 1 study, has completed, sponsored by Curis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a phase 1, open-label, multicenter dose-escalation study to determine the RP2D of CI 8993 for administration to patients with relapsed/refractory solid tumors by evaluating the safety and tolerability and characterizing the PK, PD, and anti cancer activity of CI-8993 in this population.
Interventions
- DRUG CI-8993
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2023-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04475523
The ClinicalTrials.gov registry entry for NCT04475523 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CI-8993 is the first listed.
NCT04475523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04475523 about?
NCT04475523 is a clinical study titled "Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies". This is a phase 1, open-label, multicenter dose-escalation study to determine the RP2D of CI 8993 for administration to patients with relapsed/refractory solid tumors by evaluating the safety and tolerability and characterizing the PK, PD, and anti cancer activity of CI-8993 in this population.
What is the current status of trial NCT04475523?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2020-09-22. Estimated completion is 2023-05-19.
What interventions are being tested in trial NCT04475523?
The interventions under investigation include: CI-8993 (DRUG).
Who is sponsoring clinical trial NCT04475523?
This trial is sponsored by Curis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.